Live Quote · NASDAQGMABHealthcare· Biotechnology

Genmab A/S

$28.72▼ 0.90%($-0.26)
TickerSpark Score
61/100
▌ Mixed
76
Valuation
75
Profitability
10
Growth
92
Health
50
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMAB research report →

52-Week Range54% of range
Low
$21.00
Current
$28.72
High
$35.43
Company Overviewwww.genmab.com

About the company

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines.

CEO
Jan van de Winkel
IPO
2009
Employees
2,638
HQ
Copenhagen, CD, DK

Price Chart

+30.49% · this period
$35.34$28.21$21.08Jul 17Jan 15Jul 17

Get TickerSpark's AI analysis on GMAB

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in